Database Query Results : Ramucirumab (CYRAMZA), ,

Ramu, Ramucirumab (CYRAMZA): Click to Expand ⟱
Features:
Ramucirumab (CYRAMZA) is a fully human IgG1 monoclonal antibody that binds VEGFR-2 (KDR/Flk-1) on endothelial cells and blocks VEGF-A/VEGF-C/VEGF-D from activating the receptor, thereby suppressing VEGFR-2 phosphorylation and downstream pro-angiogenic signaling (endothelial proliferation, migration, survival, and vascular permeability). Clinically, it’s used as an anti-angiogenic therapy across multiple solid tumors (labelled indications include advanced/metastatic gastric/GEJ adenocarcinoma, NSCLC in specific combinations/settings, metastatic colorectal cancer in combination therapy, and AFP-high hepatocellular carcinoma after prior therapy).

Pathways/axes ramucirumab functionally down-modulates (via VEGFR-2 blockade)
-VEGF ligand → VEGFR-2 angiogenesis axis (core target): vessel sprouting, endothelial survival, migration, permeability.
-PI3K → AKT (PKB) survival signaling downstream of VEGFR-2 (endothelial cell survival/anti-apoptosis).
-RAS → RAF → MEK → ERK (MAPK) proliferation signaling downstream of VEGFR-2 (endothelial proliferation).
-PLCγ → PKC signaling downstream of VEGFR-2 (linked to permeability and other endothelial responses).
-Src-family kinases / TSAd–Src modules and FAK/integrin–cytoskeleton signaling (migration, adhesion, barrier regulation).
-eNOS → nitric oxide (NO) signaling (vascular tone/permeability; intersects with Src and PLCγ signaling). -Vascular permeability & “vascular normalization” effects that can secondarily modulate tumor hypoxia/HIF programs and immune cell trafficking/antitumor immunity in the microenvironment (context-dependent).
Scientific Papers found: Click to Expand⟱
5268- Ramu,    A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)
- Trial, HCC, NA
other↝,
5283- Ramu,    Ramucirumab
- Review, Var, NA
VEGFR2↓,
5284- Ramu,    https://pmc.ncbi.nlm.nih.gov/articles/PMC4131847/
- Review, Var, NA
VEGFR2↓, OS↑, angioG↓, toxicity↝, ChemoSen↑, Dose↝,
5285- Ramu,  docx,    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
- Trial, NSCLC, NA
OS↑,
5286- Ramu,    Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
- Review, GC, NA
VEGFR2↓, OS↑, toxicity↝,
5287- Ramu,    Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
- in-vivo, GC, NA
VEGFR2↓, OS↑, OS↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Transcription & Epigenetics ⓘ

other↝, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 4,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,  

Functional Outcomes ⓘ

OS↑, 5,   toxicity↝, 2,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:229  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page